| Date | Title | | | 09/08/10 | AtriCure Announces September Investor Conference Schedule| WEST CHESTER, Ohio, Sep 08, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems and systems for the exclusion of the
left atrial appendage, today announced that it will participate in the
following investor conferences during September:
The UBS Global Life Sciences Conference at the Grand Hyatt New York.
Management is scheduled to present at 3:00 p.m. Eastern Ti... |
|  | | 08/04/10 | AtriCure Reports Record Second Quarter 2010 Financial Results| Highlights
Revenue of $14.2 million - strengthening U.S. revenues of $11.8 million
Positive cash from operations during the quarter of $1.1 million
Loss from operations improves 58 percent - record low of $0.4 million
Obtained commitment to expand borrowing capacity under existing credit
facility
Obtained FDA clearance and initiated launch of the AtriClipTM
... |
| | | 07/15/10 | AtriCure Announces August Investor Conference Schedule| WEST CHESTER, Ohio, Jul 15, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems, today announced that it will
participate in the following investor conferences during August:
The BMO Capital Markets 10th Annual Focus on Healthcare
Conference at the Sheraton New York Hotel and Towers. Management is
scheduled to present at 11:15 a.m. on Thursday, August 5, 2010.... |
| | | 07/14/10 | AtriCure to Announce Second Quarter 2010 Financial Results| WEST CHESTER, Ohio, Jul 14, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation products, will release its financial results
for the second quarter ended June 30, 2010 on Wednesday, August 4, 2010.
AtriCure will host a conference call at 10:00 a.m. Eastern Time on
Wednesday, August 4, 2010 to discuss its second quarter 2010 financial
results. A live web cast of the conference call will be av... |
| | | 06/14/10 | AtriCure's AtriClip(TM) System Receives FDA 510(k) Clearance| WEST CHESTER, Ohio, Jun 14, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems, today announced that it received
clearance from the FDA for its AtriClip Gillinov-Cosgrove Left Atrial
Appendage Exclusion system. The AtriClip system is designed to safely
and effectively exclude the left atrial appendage. Initial launch in the
United States is anticipated to begin later this month w... |
| | | 05/25/10 | AtriCure Announces June Investor Conference Schedule| WEST CHESTER, Ohio, May 25, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems, today announced that it will
participate in the following investor conferences during June:
The Noble Financial Sixth Annual Equity Conference at the Hard Rock
Hotel in Hollywood, Florida. Management is scheduled to present at
9:30 a.m. Eastern Time on June 8, 2010.
... |
| | | 05/10/10 | AtriCure Reports First Quarter 2010 Financial Results| Highlights
Revenues of $14 million; strongest performance of the past six quarters
International revenues up 27% to $2.9 million
DEEP AF feasibility trial approved by the FDA
WEST CHESTER, Ohio, May 10, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems, today announced revenues of $14.0
million for its first qua... |
| | | 05/10/10 | AtriCure Announces Conditional Approval of DEEP AF Feasibility Trial| WEST CHESTER, Ohio, May 10, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems, today announced that it has received
conditional approval from the FDA to evaluate the safety and efficacy of
a dual epicardial/ endocardial procedure (DEEP), or hybrid procedure, to
treat patients with persistent and long-standing persistent atrial
fibrillation (AF). The trial will be conducted at fi... |
| | | 04/27/10 | AtriCure to Present at the Ninth Annual JMP Securities Research
Conference| WEST CHESTER, Ohio, Apr 27, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems, today announced that it will
participate in the Ninth Annual JMP Securities Research Conference at
The Ritz-Carlton hotel in San Francisco, California on Tuesday, May 11,
2010. David J. Drachman, President and Chief Executive Officer, is
scheduled to present at 9:00 a.m. Eastern Time.
A live audio ... |
| | | 04/23/10 | AtriCure to Announce First Quarter 2010 Financial Results| WEST CHESTER, Ohio, Apr 23, 2010 (BUSINESS WIRE) --AtriCure, Inc. (Nasdaq:ATRC), a medical device company and a leader in
cardiac surgical ablation products, will release its financial results
for the first quarter ended March 31, 2010 on Monday, May 10, 2010.
AtriCure will host a conference call at 5:00 p.m. Eastern Time on
Monday, May 10, 2010 to discuss its first quarter 2010 financial
results. A live web cast of the conference call will be available online ... |
| | | 03/03/10 | AtriCure to Present at 22nd Annual Roth OC
Growth Stock Conference| WEST CHESTER, Ohio, Mar 03, 2010 (BUSINESS WIRE) -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems, today announced that it will
participate in the Roth Capital Partners 22nd Annual OC
Growth Stock Conference at the Ritz-Carlton Laguna Niguel in Dana Point,
California on Monday, March 15, 2010. David J. Drachman, President and
Chief Executive Officer, is scheduled to present at 3:00 p.m. Pacific
... |
| | | 02/18/10 | AtriCure Reports Fourth Quarter and Full Year 2009 Financial Results|
Highlights Fourth quarter revenues up 14.4 percent to $13.8 million
2009 record adjusted EBITDA of $1.6 million - improvement of $7.2 million
2009 cash provided by operations of $0.4 million - improvement of $6.1 million
2009 record international sales of $10.4 million - up 24.9 percent
Definitive settlement agreement executed with the DOJ
WEST CHESTER, Ohio, Feb 18, 2010 (BUSINESS WIRE) -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation... |
| | | 02/05/10 | AtriCure to Announce Fourth Quarter and Full Year 2009 Financial
Results| WEST CHESTER, Ohio, Feb 05, 2010 (BUSINESS WIRE) -- AtriCure, Inc. (NASDAQ:ATRC), a medical device company and a leader in
cardiac surgical ablation products, will release its financial results
for the fourth quarter and year ended December 31, 2009 on Thursday,
February 18, 2010.
AtriCure will host a conference call at 10:00 a.m. Eastern Time on
Thursday, February 18, 2010 to discuss its fourth quarter and full year
2009 financial results. A live web cas... |
| | | 02/02/10 | AtriCure Announces Definitive Settlement with the Department of
Justice| WEST CHESTER, Ohio, Feb 02, 2010 (BUSINESS WIRE) -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems, today announced that it has executed
a definitive agreement with the Department of Justice (DOJ) and the
Office of Inspector General of the Department of Health and Human
Services to resolve the issues raised in the DOJ's investigation and the
related qui tam complaint regarding the marketing of the ... |
| |
|
